MedTrace Logo

Contrast-Enhanced Ultrasound Ability in the Characterization of Ovarian Masses

NCT00248820 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2007-11-22

No results posted yet for this study

Summary

This study intends to assess the ability of contrast-enhanced ultrasound in the detection of benign and malignant ovarian masses compared to unenhanced ultrasound.

By using an intravascular contrast agent, this noninvasive and feasible imaging technique will allow the investigators to define specific microcirculation patterns in 100 women with ovarian lesions.

The intravascular contrast agent properties will be compared between benign and malignant adnexal masses.

The final purpose of this ultrasonography is to allow the early detection of tumors and to improve the characterization between benign and malignant lesions.

Conditions

  • Ovarian Tumor

Interventions

PROCEDURE

Contrast-enhanced ultrasound

Contrast enhanced ultrasound using Sonovue / 2.4 ml per injection - one or two injections (maximum of 9.6 ml).

Sponsors & Collaborators

  • University Hospital, Tours

    lead OTHER

Principal Investigators

  • Henri Marret, PR · Service de Gynécologie Obstétrique - Centre Olympe de Gouges CHRU Tours

  • François Tranquart, PR · Centre d'Innovation Technologique - CHRU Tours

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-09-30
Completion
2009-02-28

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00248820 on ClinicalTrials.gov